Skip to main content

Fiscal Wizard · Single-issue tearsheet

GILD / Aug 31, 2026 Run #19098

GILD

Gilead Sciences, Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

Composite verdict

A 81.0 / 100
Bullish setup · Trend Following 17 drivers · 2 gates blocking
  • Trendline Break
  • Keltner Channels
  • Rate of Change
Consider long call target Δ ~0.70 · ~35 DTE Bullish setup, Grade A → ITM call target

Industry rank 1st of 9 in Drug Manufacturers - General

rescore-sweep
Technical synthesisRegime: uptrend
Bull 100%Evidence: High · 21 signals0% Bear
Momentum Bullish 98Mean-reversion Neutral 50

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -82%
Asset value $18.31Earnings power value $64.01Price $146.23

Priced above its no-growth earnings power value ($64.01/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Above average

61.9 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EPS Growth (YoY) 100
Margin of Safety 0
Payout Ratio 83
Cash Conversion Cycle 0
Cash Conversion 81
PEGY 1

Technicals Bullish

100.0 / 100

Bullish setup leads (Trendline Break, Keltner Channels, Rate of Change); bears gated by guards. · 44 signals shown.

Strongest
Weakest
Trendline Break 84
Rate of Change 83
Vortex Signal 82

Risk Gates

2 blocking 6 caution

2 guards active, 19 signals gated.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Debt-to-Assets Caution

High debt-to-assets blocks bullish signals — balance-sheet leverage risk.

Debt-to-Equity Caution

High debt-to-equity blocks bullish signals — leverage risk.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for GILD.